NOVEL Health Strategies team is presenting 16 studies at ISPOR Annual Meeting in Milan, Italy on market access strategy, pricing and health economic and outcomes research trends.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

In-person replays of all presentations are available upon request.

Two of our Presentations Won ISPOR's Poster Award Finalist Honor.

Download PDFs of some of the already released presentations

PROBIOTICS SIGNIFICANTLY REDUCE MORTALITY IN PRETERM NEWBORNS WITH NECROTISING ENTEROCOLITIS: RESULTS OF LARGE NETWORK META-ANALYSIS (PDF)

IMPACT OF ESSENTIAL HEALTH BENEFITS ON US MARKET ACCESS (PDF)

NETWORK META-ANALYSIS ON PREVENTION OF STROKE FOR PATENT FORAMEN OVALE CLOSURE (PDF)

POLICY IMPLICATIONS OF AFFORDABLE CARE ACT ON US MARKET ACCESS (PDF)

PCV129: SYSTEMATIC REVIEW OF HYPERKALEMIA DUE TO ANGIOTENSIN ENZYME CONVERTING INHIBITORS

PCV12: NETWORK META-ANALYSIS TO ASSESS COMPARATIVE EFFECTIVENESS OF BETA-BLOCKERS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

PCV75: TRENDS IN EMERGENCY ROOM VISITS DUE TO HYPERKALEMIA IN THE UNITED STATES

PSS63: REVIEW OF PATIENT REPORTED OUTCOMES IN GLAUCOMA

PCN50: SYSTEMATIC REVIEW OF BURDEN OF CUTANEOUS T-CELL LYMPHOMA

PMD16: NETWORK META-ANALYSIS ON PREVENTION OF STROKE FOR PATENT FORAMEN OVALE CLOSURE

PCN56: SYSTEMATIC REVIEW OF BURDEN OF PANCREATIC CANCER

PSY10: COMPARISON OF NETWORK META-ANALYSIS AND TRADITIONAL META-ANALYSIS FOR PREVENTION OF RELAPSES IN MULTIPLE SCLEROSIS

PIN6: PROBIOTICS SIGNIFICANTLY REDUCE MORTALITY IN PRETERM NEWBORNS WITH NECROTISING ENTEROCOLITIS: RESULTS OF LARGE NETWORK META-ANALYSIS

PHP155: SYSTEMATIC REVIEW OF FDA BREAKTHROUGH THERAPY DESIGNATED PRODUCTS

PHP21: POLICY IMPLICATIONS OF AFFORDABLE CARE ACT ON US MARKET ACCESS

PHP187: IMPACT OF ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MARKET ACCESS

PHP189: ULTRA ORPHAN AND CANCER DRUG PRICING TRENDS IN THE US AND THE UK

PHP107: SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES

PHP184: OVERVIEW OF NUB PROCESS FOR IN-PATIENT DRUGS AND DEVICES IN GERMANY

PHP11: SYSTEMATIC REVIEW ON USE OF ECONOMIC EVIDENCE IN CLINICAL GUIDELINES